Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of trastuzumab emtansine vs capecitabine + lapatinib in HER2-positive metastatic breast cancer
CTR20170095Phase 3Completed
- Sponsor
- Roche
- Start
- Feb 2017
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab emtansine in breast cancer, sponsored by Roche. Started Feb 2017; status: completed.
02
Drugs
trastuzumab emtansine
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20170095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170095.